Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid:: a comparison with quinupristin-dalfopristin

被引：44
|
作者：
Raad, II
Hanna, HA
Hachem, RY
Dvorak, T
Arbuckle, RB
Chaiban, G
Rice, LB
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Infect Dis, Infect Control & Employee Hlth Unit 402, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Div Pharma, Houston, TX 77030 USA
[3] Louis Stokes Cleveland VA, Med Serv, Cleveland, OH USA
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2004年 / 48卷 / 09期
关键词：
D O I：
10.1128/AAC.48.9.3583-3585.2004
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
The susceptibility of 135 vancomycin-resistant Enterococcus faecium bacteremic isolates to linezolid and quinupristin-dalfopristin was determined. All were susceptible to linezolid, while 88% were susceptible to quinupristin-dalfopristin prior to the clinical use of the drugs at our hospital. More than 6 months after their clinical use, a decrease in susceptibility was noted for only linezolid at 83%. This was related in part to a single G2576U gene mutation in domain V of the 23S rRNA gene.
引用
收藏
页码：3583 / 3585
页数：3
相关论文
共 50 条
  • [1] Susceptibility of vancomycin-resistant enterococcus faecium (VREF) to linezolid and quinupristin/dalfopristin
    McLeroth, PL
    Sordillo, EM
    Polsky, B
    [J]. CLINICAL INFECTIOUS DISEASES, 2001, 33 (07) : 1178 - 1178
  • [2] Vancomycin-resistant Enterococcus faecium osteomyelitis:: Successful treatment with quinupristin-dalfopristin
    Summers, M
    Misenhimer, GR
    Antony, SJ
    [J]. SOUTHERN MEDICAL JOURNAL, 2001, 94 (03) : 353 - 355
  • [3] Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections
    Raad, I
    Hachem, R
    Hanna, H
    Afif, C
    Escalante, C
    Kantarjian, H
    Rolston, K
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (04) : 646 - 649
  • [4] Quinupristin-dalfopristin versus linezolid for the treatment of vancomycin-resistant Enterococcus faecium bacteraemia: Efficacy and development of resistance
    Chong, Yong Pil
    Lee, Sang-Oh
    Song, Eun Hee
    Lee, Eun Jung
    Jang, Eun-Young
    Kim, Sung-Han
    Choi, Sang-Ho
    Kim, Mi-Na
    Jeong, Jin-Yong
    Woo, Jun Hee
    Kim, Yang Soo
    [J]. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2010, 42 (6-7) : 491 - 499
  • [5] Enterococcus faecium cholangitis resistant to vancomycin and quinupristin-dalfopristin
    Maseda, E
    Uña, R
    Ureta, P
    Royo, C
    [J]. MEDICINA CLINICA, 2002, 119 (07): : 276 - 277
  • [6] Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin
    Linden, PK
    Moellering, RC
    Wood, CA
    Rehm, SJ
    Flaherty, J
    Bompart, F
    Talbot, GH
    [J]. CLINICAL INFECTIOUS DISEASES, 2001, 33 (11) : 1816 - 1823
  • [7] Susceptibility of glycopeptide-resistant Enterococcus faecium to tigecycline, dapto-mycin, linezolid, and quinupristin-dalfopristin
    Abb, J.
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 29 : S615 - S615
  • [8] Quinupristin/dalfopristin therapy for infections due to vancomycin-resistant Enterococcus faecium
    Winston, DJ
    Emmanouilides, C
    Kroeber, A
    Hindler, J
    Bruckner, DA
    Territo, MC
    Busuttil, RW
    [J]. CLINICAL INFECTIOUS DISEASES, 2000, 30 (05) : 790 - 797
  • [9] Synergy testing of vancomycin-resistant Enterococcus faecium against quinupristin-dalfopristin in combination with other antimicrobial agents
    Matsumura, SO
    Louie, L
    Louie, M
    Simor, AE
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (11) : 2776 - 2779
  • [10] Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with synercid (quinupristin/dalfopristin)
    McNeil, SA
    Clark, NM
    Chandrasekar, PH
    Kauffman, CA
    [J]. CLINICAL INFECTIOUS DISEASES, 2000, 30 (02) : 403 - 404
12345